PUBLIC COMPANY
save$VXRTVaxart, Inc.
$VXRT0.56000.00%South San Francisco, CA, USupdated 14m ago
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc.
community read0 votes
pipeline
5
marketed
0
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Preclinical1Phase 13Phase 2
Phase 2
COVID-19 (S Protein)
Coronavirus Disease 2019 (COVID-19)
Phase 2Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Norovirus Infections
Phase 2VXAG-1.1NN
Norovirus Infections
Phase 1norovirus [strain GI.1] vaccine
Norovirus Infections
PreclinicalVXAHPV-16.1
Human Papillomavirus (HPV) Associated Cancer
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Mar 28, 26tax coverTucker Sean · SVP, Chief Scientific Officer3,924 sh
- Mar 28, 26tax coverCummings James F. · Chief Medical Officer3,292 sh
- Mar 24, 26tax coverLo Steven · President, Chief Exec Officer126,028 sh
- Mar 24, 26tax coverBerg Edward B · SVP, General Counsel36,418 sh
- Mar 24, 26tax coverTucker Sean · SVP, Chief Scientific Officer36,418 sh
- Mar 24, 26tax coverCummings James F. · Chief Medical Officer30,551 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 14m ago
Found something off?
comments(0)
5-min edit window · permanent after that